ALSO NOTED: Isis inks deal with Pfizer; Ortho-McNeil touts trial results;Guidant discloses malfunction; and much more...

> Isis Pharmaceuticals will pocket a million-dollar payment from Pfizer in a new collaboration aimed at employing its antisense therapies in developing new treatments. Isis also stands to gain milestones and royalties in the deal. Story

> Ortho-McNeil has told a meeting of the American Urological Association that its drug dapoxetine can extend the duration of intercourse by three to four times. The drug is currently under review by the FDA. Story

> Guidant failed to disclose that a malfunction in its defibrillator caused a small number of the devices to malfunction. Story

> Dendreon reported that a Phase II trial of Provenge shows it may help prostate cancer patients in the earliest stages of the disease. Story

> Gloucester Pharmaceuticals of Cambridge, Massachusetts, has reported "significant activity" in its Phase II results for its experimental treatment for cutaneous T-cell lymphoma. Release

> Some experts say that weaning pregnant women off of antidepressants in their third trimester is a dangerous practice. Story

> Two former executives of York Pharmaceuticals in Kansas City have been charged with distributing contaminated drugs in 2000 and 2001. Story

> Roche Holding is in talks with WHO to donate up to 1 million doses of tamiflu for an international stockpile of the flu drug. Story

> Actelion has released long-term data confirming Tracleer's safety profile. Release

And Finally...

Biotechnology is being heralded in China as a new engine of economic growth. Story

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.